EPF Publishes Position Paper on ‘The Value and Pricing of Innovative Medicines’ (01/07/2020)
We are proud to announce the publication of our latest position paper entitled ‘The Value and Pricing of Innovative Medicines.’ In the context of current political priorities on ensuring access to affordable medicines and a forthcoming new Pharmaceutical Strategy for Europe, our paper contributes EPF’s perspective as a cross-disease umbrella patient organisation to the EU-level and international debate on prices and value of innovative medicines, building on our core principles of 2016.
All patients in the EU have a right to access high-quality, patient-centred care in a timely manner. Medicines form one of the most important aspects of treatment for many patients. However, there are concerns in Europe and globally that the cost of some new medicines is undermining health systems’ capacity to provide sustainable and equitable access for all. Patients will only benefit from new, innovative therapies if they are available in a timely manner, accessible and affordable to all who need them.
EPF will present this paper during an event which will take place virtually 1 July (TODAY) from 15h-17h. The event will be moderated by EPF President Marco Greco, co-hosted by MEPs Kateřina Konečná, Tomislav Sokol and Tiemo Wölken and feature a keynote speech from EU Commissioner for Health and Food Safety, Stella Kyriakides.
Download Executive Summary
Download Full Position Paper
Follow along on Twitter
EPF will be live-tweeting during the virtual launch this afternoon between 15h-17h. We ask that you follow along and address any questions or comments you may have regarding the position paper to our handle@eupatientsforum using the hashtag #AccessForPatients. Stay tuned!